Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weijing Tang is a classic Traditional Chinese Medicine (TCM) herbal formula, originally described in the 7th century. It is composed of four botanical ingredients: Phragmitis Rhizoma (Lu Gen), Benincasae Semen (Dong Gua Zi), Persicae Semen (Tao Ren), and Coicis Semen (Yi Yi Ren). Traditionally indicated for clearing Lung-Heat and resolving phlegm-stasis, it is primarily used to treat lung abscesses and respiratory infections. In modern clinical research, Weijing Tang is studied as an adjunctive treatment for chronic obstructive pulmonary disease (COPD), community-acquired pneumonia, and bronchiectasis. Its pharmacological activity is associated with the regulation of inflammatory pathways, including the reduction of pro-inflammatory cytokines such as TNF-α and IL-8, and the modulation of the pulmonary microbiota.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on weijing tang.